Bispecific antibodies for delivery into the brain

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 393-399

  Watts, Ryan J ^a   Dennis, Mark S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY;

BLOOD BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEM; ENDOTHELIUM; FOLLOW UP; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS;

ANIMALS; ANTIBODIES, BISPECIFIC; BRAIN; HUMANS; PROTEIN TRANSPORT; RECEPTORS, CELL SURFACE; TRANSCYTOSIS;

EID: 84878856619     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.03.023     Document Type: Review

References (37)

1. Graff C.P., Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003, 63:1288-1296.
2. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001, 74:7-25.
3. Tarner I.H., Muller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 2008, 5:1027-1037.
4. Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J 2010, 12:348-360.
5. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
6. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10:301-316.
7. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012, 4:182-197.
8. Riethmuller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012, 12:12.
9. Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., Heise C.E., Hoyte K., Luk W., Lu Y., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011, 3:84ra43.
10. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011, 3:84ra44.
11. Liddelow S.A. Fluids and barriers of the CNS: a historical viewpoint. Fluids Barriers CNS 2011, 8:2.
12. Pardridge W.M. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012, 32:1959-1972.
13. Tam S.J., Watts R.J. Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu Rev Neurosci 2010, 33:379-408.
14. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr 1974, 52:1158-1164.
15. Zlokovic B.V., Skundric D.S., Segal M.B., Lipovac M.N., Mackic J.B., Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 1990, 107:263-270.
16. Banks W.A., Jaspan J.B., Huang W., Kastin A.J. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997, 18:1423-1429.
17. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987, 18:299-304.
18. Friden P.M., Walus L.R., Musso G.F., Taylor M.A., Malfroy B., Starzyk R.M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci U S A 1991, 88:4771-4775.
19. Pardridge W.M., Buciak J.L., Friden P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 1991, 259:66-70.
20. de Boer A.G., Gaillard P.J. Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet 2007, 46:553-576.
21. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
22. Lichota J., Skjorringe T., Thomsen L.B., Moos T. Macromolecular drug transport into the brain using targeted therapy. J Neurochem 2010, 113:1-13.
23. Abulrob A., Sprong H., Van Bergen en Henegouwen P., Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005, 95:1201-1214.
24. Agarwal N., Lippmann E.S., Shusta E.V. Identification and expression profiling of blood-brain barrier membrane proteins. J Neurochem 2010, 112:625-635.
25. Mayle K.M., Le A.M., Kamei D.T. The intracellular trafficking pathway of transferrin. Biochim Biophys Acta 2012, 1820:264-281.
26. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312:162-163.
27. Jefferies W.A., Brandon M.R., Williams A.F., Hunt S.V. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 1985, 54:333-341.
28. Moos T., Morgan E.H. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J Neurochem 2001, 79:119-129.
29. Paris-Robidas S., Emond V., Tremblay C., Soulet D., Calon F. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol 2011, 80:32-39.
30. Roberts R.L., Fine R.E., Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993, 104:521-532.
31. Ridgway J.B., Presta L.G., Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996, 9:617-621.
32. Daneman R., Zhou L., Agalliu D., Cahoy J.D., Kaushal A., Barres B.A. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS ONE 2010, 5:e13741.
33. Iacopetta B.J., Morgan E.H., Yeoh G.C. Transferrin receptors and iron uptake during erythroid cell development. Biochim Biophys Acta 1982, 687:204-210.
34. Ponka P., Lok C.N. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999, 31:1111-1137.
35. Zhou Q.H., Boado R.J., Hui E.K., Lu J.Z., Pardridge W.M. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos 2011, 39:1149-1154.
36. Ohshima-Hosoyama S., Simmons H.A., Goecks N., Joers V., Swanson C.R., Bondarenko V., Velotta R., Brunner K., Wood L.D., Hruban R.H., et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE 2012, 7:e39036.
37. Pardridge W.M., Boado R.J. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res 2009, 26:2227-2236.